| Ribosomal stalk protein silencing partially corrects the ΔF508-CFTR functional expression defect G Veit, K Oliver, PM Apaja, D Perdomo, A Bidaud-Meynard, ST Lin, J Guo, ... PLoS biology 14 (5), e1002462, 2016 | 59 | 2016 |
| Slowing ribosome velocity restores folding and function of mutant CFTR KE Oliver, R Rauscher, M Mijnders, W Wang, MJ Wolpert, J Maya, ... The Journal of clinical investigation 129 (12), 5236-5253, 2019 | 36 | 2019 |
| Positive epistasis between disease-causing missense mutations and silent polymorphism with effect on mRNA translation velocity R Rauscher, GB Bampi, M Guevara-Ferrer, LA Santos, D Joshi, D Mark, ... Proceedings of the National Academy of Sciences 118 (4), e2010612118, 2021 | 26 | 2021 |
| Transformative therapies for rare CFTR missense alleles KE Oliver, ST Han, EJ Sorscher, GR Cutting Current opinion in pharmacology 34, 76-82, 2017 | 26 | 2017 |
| The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue CM Sabusap, D Joshi, L Simhaev, KE Oliver, H Senderowitz, ... Journal of Biological Chemistry 296, 2021 | 25 | 2021 |
| Assessing cell-specific effects of genetic variations using tRNA microarrays C Polte, D Wedemeyer, KE Oliver, J Wagner, MJC Bijvelds, J Mahoney, ... BMC genomics 20, 1-12, 2019 | 23 | 2019 |
| Impact of d-amino acid dehydrogenase on virulence factor production by a Pseudomonas aeruginosa KE Oliver, L Silo-Suh Canadian journal of microbiology 59 (9), 598-603, 2013 | 9 | 2013 |
| General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants AG McKee, EF McDonald, WD Penn, CP Kuntz, K Noguera, ... Cell Chemical Biology 30 (6), 632-642. e5, 2023 | 8 | 2023 |
| Benchmarking AlphaMissense pathogenicity predictions against cystic fibrosis variants EF McDonald, KE Oliver, JP Schlebach, J Meiler, L Plate Plos one 19 (1), e0297560, 2024 | 6 | 2024 |
| The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold? KE Oliver, MS Carlon, N Pedemonte, M Lopes-Pacheco Expert Opinion on Pharmacotherapy 24 (14), 1545-1565, 2023 | 6 | 2023 |
| Features of CFTR mRNA and implications for therapeutics development JNJ Jackson, Y Mao, TR White Jr, C Foye, KE Oliver Frontiers in Genetics 14, 1166529, 2023 | 3 | 2023 |
| Global assessment of the integrated stress response in CF patient-derived airway and intestinal tissues GB Bampi, R Rauscher, S Kirchner, KE Oliver, MJC Bijvelds, LA Santos, ... Journal of Cystic Fibrosis 19 (6), 1021-1026, 2020 | 3 | 2020 |
| Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPID DM Green, T Lahiri, KS Raraigh, F Ruiz, J Spano, N Antos, L Bonitz, ... Pediatrics 153 (5), e2023064657, 2024 | 2 | 2024 |
| Elucidation of Global Trends in the Effects of VX-661 and VX-445 on the Expression of Clinical CFTR Variants AG McKee, EF McDonald, WD Penn, CP Kuntz, K Noguera, ... bioRxiv, 2022.10. 14.512300, 2022 | 2 | 2022 |
| OPTIMIZING THE FRT MODEL FOR STUDIES OF CYSTIC FIBROSIS DISEASE MECHANISM AND DRUG DISCOVERY D Joshi, C Manfredi, A Rab, A Ehrhardt, KE Oliver, JS Hong, EJ Sorscher PEDIATRIC PULMONOLOGY 52, S221-S221, 2017 | 1 | 2017 |
| Characterization of the Role of dadA in Pseudomonas aeruginosa Virulence Factor Production KE Oliver Auburn University, 2011 | 1 | 2011 |
| Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment M Wu, JD Davis, C Zhao, T Daley, KE Oliver Journal of Clinical & Translational Endocrinology 36, 100344, 2024 | | 2024 |
| 287 A synonymous polymorphism associated with rare CFTR variants confers alterations to protein biogenesis, pharmacologic response, and clinical phenotype T White, J Jackson, A Winters, D Joshi, G Bampi, E Sorscher, Z Ignatova, ... Journal of Cystic Fibrosis 22, S144-S145, 2023 | | 2023 |
| 330 Using ribosome-directed small molecules and nucleotide-based approaches to overcome distinct subclasses of CFTR variants J Jackson, C Foye, A Winters, S Sasaki, L Huang, K Oliver Journal of Cystic Fibrosis 22, S164-S165, 2023 | | 2023 |
| 650 Ribosomal silencing confers cystic fibrosis transmembrane conductance regulator nonsense suppression and is synergistic with highly effective modulators T White, S Santos, M Icyuz, W Wang, A Rab, J Hong, E Sorscher, ... Journal of Cystic Fibrosis 21, S356-S357, 2022 | | 2022 |
